SARS-CoV-2 vaccination in IBD: more pros than cons.

D'Amico, Ferdinando; Rabaud, Christian; Peyrin-Biroulet, Laurent; Danese, Silvio

D'Amico, Ferdinando; Rabaud, Christian; Peyrin-Biroulet, Laurent; Danese, Silvio.

D'Amico F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Rabaud C; IBD Center, Humanitas Clinical and Research Center-IRCCS, Rozzano, Milan, Italy.
Peyrin-Biroulet L; Department of Infectious Disease, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.
Danese S; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France.

Nat Rev Gastroenterol Hepatol ; 18(4): 211-213, 2021 04.

Article in English | MEDLINE | ID: covidwho-1039646

Subject(s)

COVID-19 Vaccines/therapeutic use; COVID-19/prevention & control; Inflammatory Bowel Diseases/immunology; Humans; Immunosuppressive Agents/therapeutic use; Inflammatory Bowel Diseases/drug therapy; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Inflammatory Bowel Diseases / COVID-19 Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Nat Rev Gastroenterol Hepatol Journal subject: Gastroenterology Year: 2021 Document Type: Article Affiliation country: S41575-021-00420-w

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google